FDA extends review period by three months for rheumatoid arthritis candidate baricitinib
Baricitinib is being co-developed by Eli Lilly and Company and Incyte under an exclusive global license and collaboration agreement signed in December 2009. It is intended to be taken orally
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.